{
  "@context": "https://schema.org/",
  "@type": "MedicalCondition",
  "@id": "aku:vascular:genetic:vascular-ehlers-danlos",
  "name": "Vascular Ehlers-Danlos Syndrome",
  "alternateName": [
    "vEDS",
    "EDS Type IV",
    "Vascular Type EDS"
  ],
  "description": "The most severe form of Ehlers-Danlos syndrome, caused by mutations in COL3A1 affecting type III collagen. Characterized by arterial rupture, bowel perforation, and uterine rupture without significant preceding dilation. Surgery carries extremely high risk.",
  "code": [
    {
      "@type": "MedicalCode",
      "codeValue": "Q79.63",
      "codingSystem": "ICD-10-CM"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "83470001",
      "codingSystem": "SNOMED-CT",
      "name": "Ehlers-Danlos syndrome type IV"
    }
  ],
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/genetic-ctd",
    "type": "definition",
    "subtype": "connective_tissue_disorder",
    "difficulty": "advanced",
    "importance": "foundational",
    "board_yield": "HIGH",
    "aku_id": "EDS-001",
    "keywords": [
      "vascular EDS",
      "COL3A1",
      "type III collagen",
      "arterial rupture",
      "tissue fragility"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "genetic_connective_tissue"
  },
  "content": {
    "statement": "aku:vascular:genetic:vascular-ehlers-danlos is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Genetic-Ctd that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding aku:vascular:genetic:vascular-ehlers-danlos helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of aku:vascular:genetic:vascular-ehlers-danlos include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of aku:vascular:genetic:vascular-ehlers-danlos."
    }
  },
  "genetics": {
    "inheritance": "Autosomal dominant",
    "gene": "COL3A1 on chromosome 2q32.2",
    "protein": "Type III collagen (procollagen alpha 1 chain)",
    "prevalence": "1 in 50,000-200,000",
    "de_novo": "~50% of cases"
  },
  "pathophysiology": {
    "type_iii_collagen": "Major component of blood vessel walls, intestines, uterus",
    "mechanism": "Defective or reduced type III collagen production",
    "result": "Tissue fragility with spontaneous rupture WITHOUT preceding dilation",
    "key_difference": "Vessels rupture at NORMAL diameters (unlike Marfan/LDS)"
  },
  "clinical_features": {
    "major_criteria": [
      "Arterial rupture at young age",
      "Spontaneous sigmoid colon perforation",
      "Uterine rupture during pregnancy",
      "Family history of vEDS"
    ],
    "minor_criteria": [
      "Thin, translucent skin (veins visible)",
      "Characteristic facies (thin lips, small chin, thin nose, hollow eyes)",
      "Acrogeria (aged appearance of hands)",
      "Hypermobility of small joints",
      "Tendon and muscle rupture",
      "Clubfoot (talipes equinovarus)",
      "Early-onset varicose veins",
      "Arteriovenous/carotid-cavernous fistula",
      "Pneumo-/hemothorax",
      "Gingival recession"
    ],
    "vascular_complications": {
      "arterial_rupture": "Medium-sized arteries (splenic, hepatic, renal, iliac)",
      "dissection": "Less common than rupture",
      "aneurysm": "May not precede rupture",
      "age_of_event": "Mean age 23-25 years for first major event"
    },
    "gi_complications": {
      "sigmoid_perforation": "Most common GI complication",
      "spontaneous": "Without diverticular disease",
      "mortality": "High if not recognized"
    }
  },
  "diagnosis": {
    "clinical_suspicion": "Unexplained arterial rupture in young patient",
    "genetic_testing": "COL3A1 mutation analysis (definitive)",
    "biochemical": "Collagen analysis of fibroblast culture (rarely done now)",
    "villefranche_criteria": {
      "major": "4 major criteria",
      "minor": "13 minor criteria",
      "diagnosis": "2+ major OR 1 major + minor features + family history"
    }
  },
  "management": {
    "avoid_surgery_when_possible": {
      "rationale": "Tissue fragility makes surgery extremely high risk",
      "complications": "Anastomotic dehiscence, arterial injury, bleeding"
    },
    "conservative_management": {
      "arterial_hemorrhage": "Endovascular preferred over open when possible",
      "gi_perforation": "Minimal surgery, staged approach"
    },
    "medical": {
      "celiprolol": "Beta-blocker shown to reduce vascular events in trial",
      "blood_pressure": "Maintain low-normal",
      "avoid": "Contact sports, intense exercise, colonoscopy"
    },
    "pregnancy": {
      "extremely_high_risk": "12% maternal mortality reported",
      "uterine_rupture": "Can occur in any trimester",
      "delivery": "Planned cesarean in tertiary center"
    },
    "surgical_principles_if_needed": [
      "Avoid clamping (use balloon occlusion)",
      "No vessel retraction (friable tissue)",
      "Buttressed sutures",
      "Avoid tension",
      "Experienced surgeon essential"
    ]
  },
  "prognosis": {
    "life_expectancy": "Median survival 51 years",
    "first_complication": "80% have major complication by age 40",
    "cause_of_death": "Arterial rupture most common"
  },
  "clinical_pearls": [
    "Vessels RUPTURE without DILATING first - unlike Marfan/LDS",
    "Surgery is LAST RESORT due to tissue fragility",
    "Celiprolol (beta-blocker) shown to reduce events",
    "Thin translucent skin with visible veins = think vEDS"
  ],
  "semantic_relations": {
    "broader": [
      "aku:vascular:genetic-ctd:overview"
    ],
    "narrower": [],
    "related": [
      "aku:vascular:genetic:marfan-syndrome",
      "aku:vascular:genetic:loeys-dietz",
      "aku:vascular:trauma:iatrogenic"
    ]
  },
  "learning_objectives": [
    "Explain why vEDS patients rupture vessels at normal diameters",
    "Describe the surgical risks in vascular Ehlers-Danlos syndrome",
    "Outline management strategies that minimize surgical intervention"
  ],
  "relationships": {
    "prerequisites": [],
    "enables": [
      {
        "id": "aku:vascular:genetic:eds-002-col3a1",
        "title": "COL3A1 Mutations",
        "strength": 1.0,
        "reason": "Foundation for understanding genetics"
      },
      {
        "id": "aku:vascular:genetic:eds-003-surgical-avoidance",
        "title": "Surgical Avoidance",
        "strength": 1.0,
        "reason": "Foundation for management approach"
      }
    ],
    "related": [
      {
        "id": "aku:vascular:genetic:marfan-syndrome",
        "type": "differential_diagnosis",
        "relationship": "Different mechanism, aneurysmal dilation precedes rupture"
      }
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). aku:vascular:genetic:vascular-ehlers-danlos. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  },
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-06T02:34:00.000Z",
    "updated": "2026-01-06T02:34:00.000Z",
    "contributors": [
      "copilot"
    ],
    "status": "enhanced",
    "confidence": 0.95,
    "modified": "2026-01-09T11:29:00.000Z"
  }
}